IP Library Granted Patent US 7,727,752
Granted Patent B2
US 7,727,752 · App. 11/485,957 · Granted Jun 1, 2010

Kinase and phosphatase assays

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,727,752
App. No.
11/485,957
Granted
Jun 1, 2010
Kind
B2
Abstract

Compositions, methods, and kits for detecting and monitoring kinase, phosphatase and protein post-translational modification activity are described. The compositions typically include a peptide, a detectable moiety, and a protease cleavage site. Modification of a peptide by a kinase, phosphatase or other protein post-translational modification alters the proteolytic sensitivity of the peptide, resulting in a change of a detectable property of the composition. Panel assays for determining substrates or modulators of kinase, phosphatase or other protein post-translational modification activity are also described.

Claims (38)

1. A method for identifying a modulator of activity of a kinase, comprising:

a) forming a kinase mixture comprising a protein kinase, a composition, and a test compound;

b) contacting the kinase mixture with a protease to form a protease mixture;

c) forming a control mixture comprising the protein kinase, the composition, and the protease; and

d) comparing a measurable property in the protease mixture to the measurable property in the control mixture,

wherein the test compound is identified as a modulator of activity of the kinase if the measurable property in the protease mixture is different from the measurable property in the control mixture, and

wherein the composition comprises:

(i) a peptide having a length from five to fifty amino acids, the peptide comprising a motif, wherein the motif is:

TX 1 YVA, where X 1 can be G, A, or E (SEQ ID NO: 10);

(ii) a first detectable moiety, wherein the first detectable moiety is associated with the peptide; and

(iii) a protease cleavage site, wherein the protease cleavage site is located in a position relative to the motif such that enzymatic modification of the motif alters the proteolytic cleavage of the peptide;

wherein the protein kinase is selected from the group consisting of CSF 1 R,FLT 3 , and c-Kit.

2. The method of claim 1 , wherein the first detectable moiety is covalently linked to the peptide.

3. The method of claim 1 , wherein the protease cleavage site is selected from the group consisting of a chymotrypsin protease cleavage site, a caspase 3 protease cleavage site, a cathepsin G protease cleavage site, a trypsin protease cleavage site, an elastase protease cleavage site, an endoproteinase Asp-N protease cleavage site, and an endoproteinase Glu-N protease cleavage site.

4. The method of claim 1 , wherein the peptide has a length selected from the group consisting of from 8 to 50 amino acids, from 8 to 25 amino acids and from 8 to 15 amino acids.

5. The method of claim 1 , further comprising a second detectable moiety associated with the peptide.

6. The method of claim 1 , wherein the measurable property is an optical property, a magnetic property, or a radioactive property.

7. The method of claim 6 , wherein the optical property is selected from the group consisting of a molar extinction coefficient at an excitation wavelength, a quantum efficiency, an excitation spectrum, an emission spectrum, an excitation wavelength maximum, an emission wavelength maximum, a ratio of excitation amplitudes at two wavelengths, a ratio of emission amplitudes at two wavelengths, an excited state lifetime, an anisotropy, a polarization of emitted light, a resonance energy transfer, and a quenching of emission at a wavelength.

8. The method of claim 6 , wherein the optical property is selected from the group consisting of a fluorescence excitation spectrum, a fluorescence emission spectrum, a fluorescence excitation wavelength maximum, a fluorescence emission wavelength maximum, a ratio of fluorescence excitation amplitudes at two wavelengths, a ratio of fluorescence emission amplitudes at two wavelengths, a fluorescence excited state lifetime, a fluorescence anisotropy, and a quenching of fluorescence emission at a wavelength.

9. The method of claim 5 , wherein the first or second detectable moiety is selected from the group consisting of 5-FAM, 6-FAM, 7-hydroxycoumarin-3-carboxamide, 6-chloro-7-hydroxycoumarin-3-carboxamide, fluorescein-5-isothiocyanate, dichlorotriazinylaminofluorescein, tetramethylrhodamine-5-isothiocyanate, tetramethylrhodamine-6-isothiocyanate, succinimidyl ester of 5-carboxyfluorescein, succinimidyl ester of 6-carboxyfluorescein, 5-carboxytetramethylrhodamine, 6-carboxymethylrhodamine, fluorescein maleimide, and 7-amino- 4-methylcoumarin- 3-acetic acid.

10. The method of claim 5 , wherein the first detectable moiety, the second detectable moiety or the first and second detectable moiety is a member of a specific binding pair.

11. The method of claim 5 , wherein the first detectable moiety and the second detectable moiety form a dark quenching RET pair or a FRET pair.

12. The method of claim 5 , wherein the first detectable moiety is 7-hydroxycoumarin-3-carboxamide and the second detectable moiety is 5-FAM.

13. The method of claim 5 , wherein the first or second detectable moiety is covalently linked to the peptide via a linker (L).

14. The method of claim 13 , wherein the L is selected from the group consisting of GABA, diaminopentanyl, and aminohexanoyl.

15. A method for identifying a modulator of activity of a kinase, comprising:

a) forming a kinase mixture comprising a protein kinase, a composition, and a test compound;

b) contacting the kinase mixture with a protease to form a protease mixture;

c) forming a control mixture comprising the protein kinase, the composition, and the protease; and

d) comparing a measurable property in the protease mixture to the measurable property in the control mixture,

wherein the test compound is identified as a modulator of activity of the kinase if the measurable property in the protease mixture is different from the measurable property in the control mixture, and

wherein the composition comprises:

(i) a peptide having a length from five to fifty amino acids, the peptide comprising a motif, wherein the motif is TX 1 YVA, where X 1 can be G, A, or E (SEQ ID NO: 10);

(ii) a first detectable moiety, wherein the first detectable moiety is associated with the peptide; and

(iii) a protease cleavage site, wherein the protease cleavage site is associated with the peptide and is selected from the group consisting of a chymotrypsin protease cleavage site, a caspase 3 protease cleavage site, a cathepsin G protease cleavage site, a trypsin protease cleavage site, an elastase protease cleavage site, an endoproteinase Asp-N protease cleavage site, and an endoproteinase Glu-N protease cleavage site,

wherein the protease cleavage site may overlap with or encompass the motif, and

wherein the protein kinase is selected from the group consisting of CSF1R, FLT3, and c-Kit.

16. The method of claim 1 , wherein the motif comprises TX 1 YVA, where X 1 can be G, A or E (SEQ ID NO: 10), and wherein X 1 is A.

Assignments (3)
LIEN RELEASE Recorded Apr 9, 2013
From: BANK OF AMERICA, N.A.
To: LIFE TECHNOLOGIES CORPORATION
Reel/Frame 030182/0461 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 11, 2010
From: KLINK, TONY; BEEBE, JANE; LASKY, DAVID; KLEMAN-LEYER, KAREN; SOMBERG, RICHARD
To: LIFE TECHNOLOGIES CORPORATION
Reel/Frame 023927/0068 →
SECURITY AGREEMENT Recorded Dec 5, 2008
From: LIFE TECHNOLOGIES CORPORATION
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 021975/0467 →